“Ozempic muscle loss” is one of the loudest claims in this category, and the body composition data are more reassuring than the headlines — and more useful than the reassurance. Both halves of that matter.
Roughly a quarter to a third of the weight lost on these drugs is lean tissue, which is what happens in any substantial weight loss — the evidence does not support the claim that GLP-1s selectively strip muscle. In STEP 1, lean mass as a share of body weight actually rose by 3 percentage points. But the absolute amounts are large: SURMOUNT-1 participants lost about 15.9 kg of fat and 5.6 kg of lean tissue. Protein of 1.2 to 1.5 g per kg per day plus resistance training is the mitigation, and it is well evidenced.

What the scans actually showed
Body composition sub-studies used DEXA scanning to separate fat from lean tissue. The results:
| Trial | What was lost |
|---|---|
| STEP 1 (semaglutide) | Total fat mass fell 19.3%; lean body mass fell 9.7%. Lean mass as a proportion of body weight rose by 3.0 percentage points. |
| SURMOUNT-1 (tirzepatide) | About three-quarters of the loss was fat, one-quarter lean — roughly 15.9 kg of fat and 5.6 kg of lean soft tissue over 72 weeks. |
| Real-world data | Fat-free mass accounted for roughly one-quarter to one-third of total weight lost. |
The STEP 1 line is the one that undercuts the alarmist framing. Participants ended the trial with lean tissue making up a larger share of their bodies than when they started. That is the opposite of what “muscle wasting” describes.
Why “proportionate” is the key word
The reviewers’ conclusion is worth stating precisely: the findings do not support the proposition that GLP-1 therapy selectively depletes lean tissue beyond what is expected during substantial weight reduction.
All large weight loss costs lean tissue. Dieting does it. Bariatric surgery does it. Some of what is counted as “lean mass” on a scan is not muscle at all — it includes water, glycogen, connective tissue, and the metabolically active tissue that supports a larger body and is genuinely no longer needed at a smaller one. A man who loses 22 kg does not require the same amount of supporting structure he did before.
One honest qualification the same literature offers: bariatric surgery produced a more favourable fat-to-lean loss ratio than GLP-1 treatment in the comparisons made. So the drugs are not the best-performing option on this specific measure, even though they are not the outlier the headlines suggest.
Why it still matters
Proportionate is not the same as trivial, and this is where the reassuring coverage overshoots.
Losing 5.6 kg of lean tissue is a real amount of tissue. And unlike fat, it is not automatically recovered — weight regained after stopping tends to come back disproportionately as fat. A man who cycles on and off a GLP-1 without training can end up at a similar weight with a worse body composition than he started with.
Lean tissue also does work. It is where most glucose is disposed of, it drives resting metabolic rate, and it determines strength and physical function. Losing it is not merely cosmetic.
Why this lands differently for men
Three reasons the calculus is not identical to a woman’s.
Men start with more absolute muscle mass, so the same percentage loss is more tissue. Men over about 40 are already losing muscle to age-related sarcopenia, and a drug-driven loss stacks on top of that rather than replacing it. And on a men’s health site it is worth adding: weight loss raises testosterone measurably, and testosterone supports muscle maintenance — so getting the fat off has an effect that runs in your favour, provided you are giving the muscle a reason to stay.
Which is the whole point of the next two sections. The mitigation is not exotic.
Protein: the number
The recommendation from the review literature is 1.2 to 1.5 grams of protein per kilogram of body weight per day during active weight loss, with the supporting evidence pointing to intakes above roughly 1.3 g/kg being associated with better muscle preservation.
For a 100 kg man that is 120 to 150 grams a day. For a 90 kg man, 108 to 135.
The practical difficulty is specific to these drugs and worth naming: they suppress appetite, protein is filling, and early satiety means many people simply eat less of everything — including the macronutrient they most need to protect. Hitting a protein target on a drug designed to make you not want food takes deliberate planning, usually front-loading protein earlier in the day when appetite is better.
Resistance training
The evidence here is consistent: exercise-containing interventions outperform diet-only or drug-only approaches for preserving lean tissue.
The stimulus that tells the body to keep muscle during an energy deficit is loading it. Cardiovascular exercise has its own substantial benefits — including, separately, a measurable effect on erectile function — but it is not the signal that preserves muscle.
What that looks like in practice is unglamorous: two or three resistance sessions a week, working the major movements, with enough load that the last repetitions are genuinely hard. You are not trying to build muscle in a calorie deficit. You are trying to give the body a reason not to break down what is already there.
Started early, this is the difference between losing weight and losing fat. Started after a year on the drug, some of the tissue is already gone.
Sources
- Lean mass and musculoskeletal preservation in GLP-1-based obesity treatment: nutrition, exercise, supplementation, and monitoring strategies. Metabolites, 2026. Metabolites
- Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes, Obesity and Metabolism, 2024. PubMed
- Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism, 2022. PubMed
This article is for information only and is not medical advice. It cannot account for your individual circumstances. Talk to a doctor about your own situation, particularly before starting or stopping any prescription medication.
